Non-Alcoholic Fatty Liver Disease (NAFLD) Market | Insight Market Data

Executive Overview & Market Definition

The Non-Alcoholic Fatty Liver Disease (NAFLD) market—now clinically reframed as metabolic dysfunction-associated steatotic liver disease (MASLD)—is transitioning from a diagnosis of exclusion into a high-value, pharmacologically active metabolic disorder. Our proprietary primary research estimates the global NAFLD therapeutic and diagnostic market at USD 20.33 billion in 2026, on a trajectory to reach USD 42.32 billion by 2031, expanding at a 15.79% CAGR over the forecast window.

This inflection is structural rather than cyclical. The March 2024 accelerated approval of resmetirom (Rezdiffra) marked the first disease-specific therapy for noncirrhotic MASH with F2–F3 fibrosis, ending a decades-long void in which clinicians relied almost exclusively on off-label vitamin E, pioglitazone, and lifestyle intervention. Our expert interviews with hepatologists and payer medical directors confirm that this single approval has reset the commercial architecture of the entire category.

Key structural metrics underpinning our base case:

• Approximately 33% of the global adult population met MASLD criteria in 2020, with projections crossing 41% by 2050.
• An estimated 83% of patients meeting MASLD criteria remain undiagnosed—the single largest addressable headroom in metabolic hepatology.
• U.S. MASH cases requiring pharmacologic intervention are projected to double to roughly 12 million patients.
• The adjacent NASH-specific treatment segment alone is forecast to grow from USD 12.5 billion in 2026 to USD 33.8 billion by 2030.

Market Drivers & Growth Mechanics

Our demand-side modeling isolates six principal drivers, each weighted by observed impact on the forecast CAGR.

Growing Global NAFLD Patient Pool (+4.2% CAGR impact, long-term). The terminology shift from NAFLD to MASLD removed a diagnostic stigma and materially accelerated primary-care case finding. High-frequency genetic variants (notably PNPLA3) in several Asia-Pacific populations elevate regional susceptibility, reinforcing the long-term opportunity outside Western markets. Pediatric NAFLD lengthens lifetime therapy horizons.

Escalating Obesity and Type-2 Diabetes Prevalence (+3.8%, medium-term). Type 2 diabetes confers a 65% likelihood of MASLD, versus 25–30% in the general population. Medicare's 2026 reimbursement decision for anti-obesity medicines removes a critical cost barrier for an aging, metabolically high-risk cohort. GLP-1 receptor agonists demonstrated 62.9% MASH resolution in Phase 3, validating the weight-and-liver dual-benefit thesis.

AI-Enabled Non-Invasive Diagnostics (+2.9%, short-term). Machine-learning algorithms applied to electronic health record data achieve 96% sensitivity and 92.5% specificity in fatty liver detection. Portable ultrasound platforms deliver an AUC of 0.846 for moderate steatosis, while combined ML-plus-elastography tools reach 0.80 AUC for MAFLD risk stratification in primary care.

Expanding Public-Sector Screening (+2.1%). FIB-4-based two-step algorithms have demonstrated acceptable incremental cost per QALY in 40–49-year-olds, encouraging payer adoption. The American Heart Association's 2025 cardio-liver-metabolic guidelines formalize MASLD screening for cardiovascular patients, institutionalizing detection in high-risk cohorts. Major payers now reimburse non-invasive fibrosis testing.

Multi-Target Combination R&D (+2.4%, long-term) and reimbursement expansion for metabolic/bariatric surgery (+1.0%) complete the driver stack.

Restraints, Challenges & Unmet Needs

The most consequential restraint remains the absence of widely approved disease-modifying drugs (−2.8% CAGR impact). Only one agent holds accelerated approval in a narrowly defined F2–F3 noncirrhotic population, and continued approval is contingent on confirmatory trial verification.

• Complex disease pathogenesis—heterogeneous fibrosis pathways resist single-target intervention, driving high Phase 3 attrition.
• High cost and reimbursement friction—specialty pricing collides with fragmented payer coverage.
• Diagnostic bottleneck—liver biopsy remains the reference standard but suffers low patient acceptance due to invasiveness.
• Asymptomatic early-stage presentation compresses the treatable window and delays pharmacologic intervention.
• Preferred lifestyle modification in early fibrosis reduces near-term drug adoption.
• Off-label reliance—vitamin E and pioglitazone historically accounted for 88.31% of NASH treatment revenue, reflecting the pre-approval vacuum.

Segmentation Analysis

By Drug Class

Antioxidants commanded 28.45% of 2025 revenue, sustained by affordability and availability. Farnesoid X receptor (FXR) agonists represent the fastest-growing class at a 16.72% CAGR, while thyroid hormone receptor-beta agonists and GLP-1 receptor agonists emerge as the pivotal commercial engines through 2031.

By Distribution Channel

Hospital pharmacies led with 47.32% revenue share in 2025, reflecting concentrated specialist prescribing and infusion/injection oversight. Online pharmacies post the fastest growth at 16.65% CAGR, while retail and specialty pharmacy channels accelerate as NASH management migrates to outpatient settings.

By Route of Administration

Oral formulations captured 67.10% of 2025 market value, driven by superior compliance and the oral profile of resmetirom, pioglitazone, and vitamin E. Parenteral products advance at a 16.55% CAGR, anchored by injectable GLP-1 and combination biologics.

By Age Group

Adults represent 64.72% of 2025 market value; the geriatric cohort exhibits the highest CAGR at 18.05% through 2031, propelled by Medicare obesity-drug reimbursement and the compounding metabolic burden of aging populations.

By Disease Stage

Stage F1 dominated at 34.75% share, reflecting clinical guideline prioritization of at least mild fibrosis. Stage F0 is projected to grow fastest, given that roughly 74% of screened participants fall into the F0 category—a vast early-intervention reservoir.

Regional Outlook & Investment Opportunity Assessment

North America retains dominance at 39.55% revenue share (2025), underpinned by the first-mover approval of resmetirom, AHA cardio-liver screening guidelines, and payer reimbursement of non-invasive fibrosis tests. The U.S. NASH treatment sub-segment alone commands approximately 79% of regional value.

Asia-Pacific is the fastest-growing theater at a 16.88% CAGR, driven by high-frequency genetic susceptibility variants, rapidly rising obesity and diabetes, and expanding diagnostic infrastructure in China and India.

Europe presents a high-mortality, high-prevalence profile—NASH prevalence estimated up to 5% per European Association for the Study of the Liver data—with Ireland, Hungary, Luxembourg, and the UK recording elevated NAFLD/NASH mortality. EASL-led diagnostic pathway standardization is the primary catalyst.

Latin America and MEA remain early-stage but offer scalable screening-led volume growth, with Brazil and the Gulf states representing priority beachheads.

Competitive Landscape & Strategic White-Space

The competitive field is concentrated among a small cadre of metabolic-liver specialists and diversified large-cap pharmaceutical sponsors, with medium overall market concentration.

• Madrigal Pharmaceuticals holds the pivotal first-mover position via resmetirom (Rezdiffra).
• Novo Nordisk A/S leverages semaglutide franchises and AI-enabled discovery partnerships (including a USD 500 million co-development deal with Cellarity).
• Intercept Pharmaceuticals carries obeticholic acid (Ocaliva) exposure within the FXR class.
• Gilead Sciences, Inc. and AbbVie, Inc. anchor combination-therapy and antiviral-adjacent metabolic pipelines.
• Emerging entrants include Inventiva Pharma (lanifibranor), Galmed Pharmaceuticals (Aramchol), Genfit (elafibranor/Iqirvo), Conatus Pharmaceuticals, Raptor Pharmaceuticals, and Zydus Cadila.

Strategic white-space concentrates in three zones: (1) F0–F1 early-intervention agents paired with AI-driven screening; (2) non-invasive diagnostic-plus-therapeutic bundled pathways; and (3) combination regimens pairing incretin agonists with anti-fibrotic mechanisms.

Import/Export & Supplier Dynamics

The NAFLD market is a regulated pharmaceutical category rather than a tradable commodity, so trade analysis centers on active pharmaceutical ingredient (API) sourcing and finished-dose logistics rather than customs volume.

• API concentration risk is acute: key intermediates for FXR agonists, THR-beta agonists, and GLP-1 peptides are concentrated among a limited pool of contract development and manufacturing organizations, predominantly in Europe and Asia.
• Cold-chain dependency for injectable GLP-1 products elevates distribution cost and creates regional capacity constraints in emerging markets.
• Dual-sourcing mandates are increasingly embedded in sponsor procurement contracts following post-pandemic supply shocks.
• Localization incentives in the U.S. and EU are reshaping contract manufacturing geography, with sponsors qualifying alternate API sites to reduce single-region exposure.

Procurement strategy should prioritize qualified alternate-supplier registrations, long-dated peptide capacity reservations, and cold-chain validation in high-growth APAC and LATAM markets.